Table 2.
Clinical outcomes according to PCI complexity.
| Complex PCI (n = 3651) | Noncomplex PCI (n = 6516) | Unadjusted | P value | MV adjusted∗ | P value | |
|---|---|---|---|---|---|---|
| HR (95% CI) | HR (95% CI) | |||||
| MACEa | 280 (7.7%) | 290 (4.5%) | 1.77 (1.50–2.08) | <0.001 | 1.63 (1.38–1.92) | <0.001 |
| Death | 54 (1.5%) | 80 (1.2%) | 1.20 (0.85–1.69) | 0.307 | 1.22 (0.85–1.75) | 0.275 |
| Cardiac death | 33 (0.9%) | 39 (0.6%) | 1.50 (0.94–2.38) | 0.088 | 1.50 (0.92–2.44) | 0.108 |
| MI | 109 (3.0%) | 87 (1.3%) | 2.25 (1.70–3.00) | <0.001 | 2.16 (1.62–2.87) | <0.001 |
| Target vessel MI | 52 (1.4%) | 37 (0.6%) | 2.51 (1.64–3.82) | <0.001 | 2.50 (1.59–3.77) | <0.001 |
| Definite or probable ST | 44 (1.2%) | 27 (0.4%) | 2.91 (1.80–4.69) | <0.001 | 2.71 (1.66–4.41) | <0.001 |
| Any revascularization | 400 (11.0%) | 487 (7.5%) | 1.50 (1.32–1.72) | <0.001 | 1.38 (1.21–1.58) | <0.001 |
| TVR | 234 (6.4%) | 249 (2.9%) | 1.72 (1.44–2.05) | <0.001 | 1.56 (1.30–1.87) | <0.001 |
| TLR | 182 (5.0%) | 190 (2.9%) | 1.75 (1.43–2.14) | <0.001 | 1.59 (1.29–1.95) | <0.001 |
| Stroke | 72 (2.0%) | 94 (1.4%) | 1.35 (0.99–1.83) | 0.058 | 1.36 (1.00–1.86) | 0.053 |
| Any bleeding | 229 (6.3%) | 467 (7.2%) | 0.87 (0.74–1.01) | 0.074 | 0.91 (0.77–1.07) | 0.245 |
| Clinically relevant bleedingb | 87 (2.4%) | 191 (2.9%) | 0.80 (0.62–1.03) | 0.088 | 0.86 (0.66–1.11) | 0.238 |
Values are number of events (%) unless otherwise indicated. ∗The following covariates have been included in the Cox regression multivariable model: age, sex, current smoking, body mass index, hypertension, diabetes mellitus, chronic kidney disease, left ventricular ejection fraction, prior MI, prior revascularization (percutaneous coronary intervention and/or coronary artery bypass graft), acute coronary syndrome, mean stent diameter, hemoglobin, platelet count, type of DES implanted, and DAPT duration (as a time-adjusted covariate). BARC = Bleeding Academic Research Consortium; CI = confidence interval; HR = hazard ratio; MACE = major adverse cardiac events; ST = stent thrombosis; TVR = target vessel revascularization; TLR = target lesion revascularization; other abbreviations as in Table 1a MACE was defined as the composite of cardiac death, myocardial infarction, definite/probable stent thrombosis, or target lesion revascularization. b Clinically relevant bleeding was defined as BARC type 2, 3, or 5.